BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » Page 171

Mesenchymal Stem Cell (MSC) Products – The Cost of Winning Search Terms Online

By Leave a Comment

Marketing Cost Analysis for “Mesenchymal Stem Cell”

Because Google now controls over 50% of online searches, it is the single best resource available for analyzing online search behavior within the mesenchymal stem cell (MSC) market.

Identifying the cost of winning search terms related to MSCs is an important analysis for company executives to conduct, because it allows for the planning of cost-effective Google AdWords campaigns and because it reveals existing levels of market competition for the sale of MSC products and services. [Read more…]

Major Industry Alliance: CariCord and ClinImmune Labs Partner with International Space Medicine Consortium

By Leave a Comment

AUTHOR: Authored by Wendy Roberts, PR Director of Orca Communications Unlimited, LLC.

COMMENT BY BIOINFORMANT:  Leading global players within cord blood industry frequently attain their industry dominance through industry collaborations.  In the announcement below, released May 11, 2015, CariCord and ClinImmune Labs announce a major industry partnership that will study the survivability of umbilical cord blood stem cells under micro gravity (Micro-G) simulation.

CariCord, a private stem cell bank at the University of Colorado, is a FDA-licensed cord blood manufacturer that has processed nearly 9,000 cord blood units and released 700+ for transplantation across 150+ hospitals worldwide.  While CariCord is not as substantial in size as other key players within the U.S. cord blood industry (most notably Cord Blood Registry, ViaCord, and Cryo-Cell, respectively) the company is positioning itself for increased visibility and growth through this strategic collaboration. [Read more…]

Cord Blood World Europe – Bringing together Public and Private Banks, Clinicians & Researchers

By 2 Comments

BioInformant is excited and proud to announce our sponsorship of the Cord Blood World Europe Congress 2015 as an essential global event for those participating within the cord blood and regenerative medicine community. BioInformant is deeply committed to advancing progress with human umbilical cord blood, because cord blood contains valuable hematopoietic stem cells and cord tissue (“Wharton’s Jelly”) contains valuable mesenchymal stem cells. 

As the first and only company dedicated to tracking the stem cell market, BioInformant tracks this important market segment within our global strategic report the “Complete 2015-16 Global Cord Blood Industry Report.” We also have an entire section of our blog dedicated to breaking cord blood industry news. Additionally, we have a partnership with the Save the Cord Foundation, a non-profit dedicated to cord blood banking awareness and education, in which we run a joint awareness campaign called “Cord Blood Banking Awareness: Educating America and the World.” The campaign is a global effort to educate currently expecting parents, as well as future parents, grandparents, siblings, and friends, about the medical benefits of cord blood preservation. [Read more…]

Data is boring. Put your trust in a new-age market research firm.

By Leave a Comment

“Data is boring. Put your trust in a new-age market research firm. We’re innovative, fast, and trained in applying bioinformatics – the science of analyzing complex biological data – to the field of market research.

With 4 zettabytes of data in the world, we’ll get rid of the noise and give you just the data you need to make more revenue.”

 

FUJIFILM Acquires Cellular Dynamics International (CDI)

By Leave a Comment

CDI / FUJIFILMTOKYO and MADISON, Wis., March 30, 2015 — FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) (“Fujifilm”) and Cellular Dynamics International, Inc. (CEO: Robert Palay) (“CDI”), a leading developer and manufacturer of fully functioning human cells in industrial quantities, announced that the two companies have entered into a agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger. [Read more…]

BioInformant's World-Class Clients